Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

PURPOSE: Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Wei, Shi, Ming, Yang, Jingjing, Cao, Jiang, Xu, Linyan, Yan, Dongmei, Yao, Meixue, Liu, Hui, Li, Weidong, Zhang, Bing, Sun, Kemeng, Song, Xuguang, Sun, Cai, Jiao, Jun, Qin, Yuanyuan, Sang, Tingting, Ma, Yuanyuan, Wu, Mei, Gao, Xiang, Cheng, Hai, Yan, Zhiling, Li, Depeng, Sun, Haiying, Zhu, Feng, Wang, Ying, Zeng, Lingyu, Li, Zhenyu, Zheng, Junnian, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433814/
https://www.ncbi.nlm.nih.gov/pubmed/32608579
http://dx.doi.org/10.1002/cam4.3259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433814/
https://www.ncbi.nlm.nih.gov/pubmed/32608579
http://dx.doi.org/10.1002/cam4.3259

Ejemplares similares